Kazia Therapeutics (NASDAQ: KZIA) unveils new investor site
Rhea-AI Filing Summary
Kazia Therapeutics Limited (KZIA) reports that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. Any prior references to its former website, including www.kaziatherapeutics.com, are now intended to refer to the new URL where applicable.
The site is described as providing enhanced access to information about Kazia’s business, products, services, clinical trials, and corporate developments, and stakeholders are encouraged to review information posted there alongside press releases and SEC disclosures. The information in this report is incorporated by reference into Kazia’s existing Form F-3 registration statements.
Positive
- None.
Negative
- None.
Key Figures
Commission File Number: 000-29962
Form F-3 File No.: 333-276091
Form F-3 File No.: 333-281937
+3 more
6 metrics
Commission File Number
000-29962
Exchange Act registration file for Kazia Therapeutics Limited
Form F-3 File No.
333-276091
One of the Form F-3 registration statements incorporating this report by reference
Form F-3 File No.
333-281937
One of the Form F-3 registration statements incorporating this report by reference
Form F-3 File No.
333-294392
One of the Form F-3 registration statements incorporating this report by reference
Website launch date
August 28, 2026
Date Kazia launched its new corporate website at www.kaziatx.com
Report signature date
August 31, 2026
Date the Form 6-K was signed by the Chief Executive Officer
Key Terms
foreign private issuer, Form 6-K, Form F-3, incorporates by reference, +1 more
5 terms
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Form F-3 regulatory
"registration statements on Form F-3 (File Nos. 333-276091"
Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.
incorporates by reference regulatory
"The Company hereby incorporates by reference the information contained herein"
Exchange Act regulatory
"pursuant to the Securities Exchange Act of 1934"
A federal law that sets rules for trading securities on public exchanges, requiring companies and market participants to register, disclose regular financial information, and follow standards that promote honest, orderly markets. For investors, it matters because it creates transparency and legal protections—like stopping insider trading and ensuring timely company disclosures—so you can evaluate risks and rely on consistent rules much as players rely on a referee to keep a game fair.
FAQ
What did Kazia Therapeutics Limited (KZIA) announce in this Form 6-K?
Kazia Therapeutics Limited announced that on August 28, 2026 it launched a new corporate website at www.kaziatx.com. The company highlights that the new site offers enhanced access to information on its business, products, services, clinical trials, and corporate developments.
What is the new official website URL for Kazia Therapeutics Limited (KZIA)?
The new official website for Kazia Therapeutics Limited is www.kaziatx.com. Any prior references to the company’s website, including www.kaziatherapeutics.com, in its SEC filings should now be read to refer to this updated URL, as applicable.
How should investors interpret old Kazia (KZIA) filings that reference www.kaziatherapeutics.com?
Kazia states that any prior references in its SEC filings to its website, including www.kaziatherapeutics.com, should now be understood as referring to the new URL www.kaziatx.com, as applicable. This aligns historical disclosures with the updated website address.
Which Kazia (KZIA) registration statements incorporate this 6-K by reference?
Kazia incorporates this report by reference into its Form F-3 registration statements with File Nos. 333-276091, 333-281937, and 333-294392. This means the website-related disclosure becomes part of those shelf registration statements.
Who signed this Kazia Therapeutics Limited (KZIA) Form 6-K and when?
The report was signed on August 31, 2026 by John Friend, who is identified as the company’s Chief Executive Officer. His signature appears on behalf of Kazia Therapeutics Limited as the registrant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
